Disappointing article, not disappointing biotech

BMJ 2005; 331 doi: https://doi.org/10.1136/bmj.331.7523.1025 (Published 27 October 2005) Cite this as: BMJ 2005;331:1025
  1. Fredric J Cohen, president (fred@pharmagrowth.com)
  1. Pharma Growth Strategies LLC, 3331 Street Road, Suite 140, Bensalem, PA 19020, USA

    EDITOR—Joppi et al's critique and not biotech itself is disappointing.1

    The authors classified most of the biotech drugs (24/61) as “copycat or me too products”—pejorative terms intended to cast prejudicial doubt on a drug's value. I am familiar with one of the drugs on the copycat list, teriparatide (rhPTH1-34, Forteo, Eli Lilly), a treatment for osteoporosis. I helped …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial